JNBA Financial Advisors’s Protalix BioTherapeutics PLX Stock Holding History

JNBA Financial Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-200	Closed	-$2K	–	539
2015 Q3	$2K	Hold	200	–	–	﹤0.01%	473
2015 Q2	$4K	Hold	200	–	–	﹤0.01%	432
2015 Q1	$4K	Hold	200	–	–	﹤0.01%	441
2014 Q4	$4K	Hold	200	–	–	﹤0.01%	446
2014 Q3	$5K	Hold	200	–	–	﹤0.01%	442
2014 Q2	$7K	Hold	200	–	–	﹤0.01%	388
2014 Q1	$9K	Buy	+200	New	+$9.33K	﹤0.01%	336

Other funds holding PLX

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JNBA Financial Advisors's PLX Position: Q4 2015 in Review

JNBA Financial Advisors sold out of Protalix BioTherapeutics (PLX) in Q4 2015, closing a stake of 200 shares — an estimated $2K sold.

JNBA Financial Advisors first reported a position in PLX in Q1 2014 and held it in 7 quarters. The position peaked at $9K in Q1 2014. 31 funds tracked by Wall St. Rank hold PLX as of Q4 2015.

JNBA Financial Advisors reported no remaining Protalix BioTherapeutics position as of Q4 2015 after selling out during the quarter.
JNBA Financial Advisors sold 200 Protalix BioTherapeutics shares in Q4 2015, an estimated $2K.
JNBA Financial Advisors first reported a position in Protalix BioTherapeutics in Q1 2014 and held it in 7 quarters.
JNBA Financial Advisors's Protalix BioTherapeutics position peaked at $9K in Q1 2014.
31 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2015.

Based on JNBA Financial Advisors's 13F filing for Q4 2015, filed 27 Jan 2016.